Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Oncolytics Biotech Inc T.ONC

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  ONCY

Oncolytics Biotech, Inc., is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers.
Price: $0.90 | Change: $-0.06 | %Change: -6.25%
Volume: 481,556 | Day High/Low: 1.01/0.89 | 52 Week High/Low: 2.31/0.445
View modes: 
0 stars

RE:Accumulation by party or parties unknown!

my friend, looks like sb is pump and dump. If the MM doesn't dump, how come this heavy volume? It is very hard to break 200 days average, just entice you in!  rate and reply
5 stars

Accumulation by party or parties unknown!

In the last 12 days of trading ONC and ONCY have traded 46% of the share float of 93 million. The vast majority on the Nasdaq. This trading cannot be retail investors given the trading history more
0 stars

RE:Replying to CravenRaven Using an Analysis of Stockhouse Post

?? Who does this? Who uses phrases like End Game? Who has the time? To make a spread sheet? Jeepers Still an interesting read. Thanks  rate and reply
5 stars

RE:RBC Capital Markets’ 2015 Global Healthcare Conference

Interresting Read How much of it is true? Is this the place for such a strong position against Onc and Brad? Where do your strong opinions come from?  What is causing you to say these things?  Is more
0 stars

Replying to CravenRaven Using an Analysis of Stockhouse Post

Megalomaniac, CravenRaven? I’m a Muppet in the eyes of investment bankers, just like the many retail investors who read Stockhouse. We work hard and invest our savings in companies listed on the more
0 stars

trading on Nasdaq

over 5 mil. shares trades so far  rate and reply
5 stars

RE:RE:gap getting filled....

just hit next res at .85...tomorrow probably a gap and run towards $1...chart looking great!  rate and reply
0 stars

RE:gap getting filled....

today first day of bounce back up to first res at .81..will break that soon, jittery holders still not convinced, but chart looks great, BIO stocks still hot...resurgence to follow soon..glta  rate and reply
0 stars

RBC Capital Markets’ 2015 Global Healthcare Conference

Yesterday, Robert Kirkman, President and CEO of Oncothyreon INC (NASDAQ: ONTY) presented at RBC Capital Markets’ annual conference in New York. Brad presented at the 2014 Conference on Feb 26. more
0 stars

gap getting filled....

little gap getting hit here today....looks good to pick a few up in this area for a bounce play coming soon after this pullback and consolidation time..glta  rate and reply
0 stars

MM trader from CIBC what a joke

Anyone notice the trader from CIBC in and out of his bids/asks? What a helpless fool trying to prop the price up.  rate and reply
0 stars

Knew it

Knew I should have dumped @ $1.05 Why don't I ever pull the trigger?  UGH  rate and reply
0 stars

RE:RE:Pelareorep, Example of a Whistleblower Tip

it is time for second leg up  rate and reply
5 stars

RE:Pelareorep, Example of a Whistleblower Tip

LOL... text book megalomania... I'll give you a few minutesd to look that one up GL :oP.... thppppptttt!!!  rate and reply
0 stars

Pelareorep, Example of a Whistleblower Tip

Westcoast, Google is amazing. I searched Google using “FDA status orphan designation” to find Entering Reolysin in the product name revealed more
0 stars

oink oink

eom  rate and reply
0 stars

Seeking Alpha on ONCY

Oncolytics Bio completes enrollment in Canadian cancer trial Feb 18 2015, 12:45 ET | About: Oncolytics Biotech, Inc. (ONCY) | By: Douglas W. House, SA News Editor more
0 stars

Colorectal Phase 2 Complete

News Back to News Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study 02/18/2015   CALGARY, Feb. more
0 stars

Nice trading

High trading volumes today and closed at almost the high of day. Both of those are good signs.  rate and reply
0 stars

RE:Orphan approval

Great news.The market loves the news. $1 soon.  rate and reply